Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has an operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

Apr 26,2024: Sobi Establishes Mtn Programme with a Framework Amount of SEK 10 Billion, Publishes a Base Prospectus
Apr 25,2024: Sobi Q1 2024 Report: Strong Sales Reflecting the Strength of the Portfolio
Apr 25,2024: Swedish Orphan Biovitrum AB: Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Apr 04,2024: Notice of Annual General Meeting in Swedish Orphan Biovitrum AB

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Swedish Orphan Biovitrum AB - Key Facts
Swedish Orphan Biovitrum AB - Key Employees
Swedish Orphan Biovitrum AB - Key Employee Biographies
Swedish Orphan Biovitrum AB - Major Products and Services
Swedish Orphan Biovitrum AB - History
Swedish Orphan Biovitrum AB - Company Statement
Swedish Orphan Biovitrum AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Swedish Orphan Biovitrum AB - Business Description
Product Category: Hematology
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Specialty Care
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other
Performance
Overview
R&D Overview
Swedish Orphan Biovitrum AB - Corporate Strategy
Swedish Orphan Biovitrum AB - SWOT Analysis
SWOT Analysis - Overview
Swedish Orphan Biovitrum AB - Strengths
Swedish Orphan Biovitrum AB - Weaknesses
Swedish Orphan Biovitrum AB - Opportunities
Swedish Orphan Biovitrum AB - Threats
Swedish Orphan Biovitrum AB - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Swedish Orphan Biovitrum AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 26, 2024: Sobi Establishes Mtn Programme with a Framework Amount of SEK 10 Billion, Publishes a Base Prospectus
Apr 25, 2024: Sobi Q1 2024 Report: Strong Sales Reflecting the Strength of the Portfolio
Apr 25, 2024: Swedish Orphan Biovitrum AB: Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Apr 04, 2024: Notice of Annual General Meeting in Swedish Orphan Biovitrum AB
Feb 12, 2024: Orexo and Sobi Agree to Advance Feasibility Study with AmorphOX
Feb 08, 2024: Sobi Publishes Q4 2023 Report: Strong Revenue Performance and Growth into 2024
Jan 31, 2024: Sobi to Present New Data at EAHAD 2024
Jan 24, 2024: Sobi Announces Invitation of Q4 and FY 2023 Report
Jan 05, 2024: Sobi''s Chairman of the Board resigns due to health reasons
Oct 30, 2023: Sobi Publishes Q3 2023 Report: Strong Revenue and Solid Performance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Swedish Orphan Biovitrum AB, Key Facts
Swedish Orphan Biovitrum AB, Key Employees
Swedish Orphan Biovitrum AB, Key Employee Biographies
Swedish Orphan Biovitrum AB, Major Products and Services
Swedish Orphan Biovitrum AB, History
Swedish Orphan Biovitrum AB, Subsidiaries
Swedish Orphan Biovitrum AB, Key Competitors
Swedish Orphan Biovitrum AB, Ratios based on current share price
Swedish Orphan Biovitrum AB, Annual Ratios
Swedish Orphan Biovitrum AB, Annual Ratios (Cont...1)
Swedish Orphan Biovitrum AB, Annual Ratios (Cont...2)
Swedish Orphan Biovitrum AB, Interim Ratios
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Swedish Orphan Biovitrum AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Swedish Orphan Biovitrum AB, Performance Chart (2019 - 2023)
Swedish Orphan Biovitrum AB, Ratio Charts
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Swedish Orphan Biovitrum AB, Pharmace

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings